Harvard Bioscience INC Schedule 13G passive stakes

Leviticus Partners LP has increased its beneficial ownership of Harvard Bioscience Inc. common stock to 6.5%, acquiring 293,676 shares.

Leviticus Partners LP has disclosed a 7.6% beneficial ownership stake in Harvard Bioscience Inc., holding 3,401,601 common shares.

Leviticus Partners LP has filed an amended Schedule 13G, reporting beneficial ownership of 7.5% of Harvard Bioscience Inc.'s common stock.

Leviticus Partners LP and AMH Equity LLC have increased their beneficial ownership in Harvard Bioscience Inc. to 9.2% of common stock.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 2.5% in Harvard Bioscience Inc.'s common stock as of June 30, 2025.

Leviticus Partners LP and AMH Equity LLC have filed an amended Schedule 13G, reporting a beneficial ownership of 8.1% of Harvard Bioscience Inc.'s common stock.

Investment firm Harvey Partners, LLC has filed an amended Schedule 13G, reporting a 4.96% beneficial ownership stake in Harvard Bioscience Inc. as of March 31, 2025.

Leviticus Partners LP and AMH Equity LLC have jointly disclosed a 9.8% beneficial ownership stake in Harvard Bioscience Inc., indicating potential engagement in board nomination activities.

Weber Capital Management, LLC has filed an amended Schedule 13G, reporting a beneficial ownership of 7.26% of Harvard Bioscience Inc.'s common stock as of March 31, 2025.

Leviticus Partners LP and AMH Equity LLC have jointly disclosed a significant 8.6% beneficial ownership stake in Harvard Bioscience Inc., totaling 3,770,352 shares of common stock.

Punch & Associates Investment Management, Inc. has filed an amended Schedule 13G, reporting beneficial ownership of 0.1% of Harvard Bioscience Inc.'s common stock as of March 31, 2025.

Investment firms Leviticus Partners LP and AMH Equity LLC, managed by Adam M Hutt, have disclosed a combined beneficial ownership of 7.5% of Harvard Bioscience Inc.'s common stock.

Weber Capital Management, LLC has reported a passive beneficial ownership of 5.77% in Harvard Bioscience, Inc., holding over 2.5 million shares as of December 31, 2024.

Leviticus Partners LP and AMH Equity LLC have filed an amended Schedule 13G, disclosing a reduction in their beneficial ownership of Harvard Bioscience Inc.'s common stock to 4.9%, down from a previously held stake of 5% or more.